Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 sorted by
relevance

Admin05.10.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

7107
Admin22.08.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

5409
Admin10.09.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

3505
Admin07.10.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

56010
Admin05.09.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

2504
Admin15.07.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

6001
Admin08.10.2021

Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263

4202
Admin11.09.2021

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family

9003
Admin23.07.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

9101
Admin17.08.2021

Navitoclax (ABT-263) | Bcl-2 inhibitor | Read Reviews

8603
Admin25.09.2021

Apoptosis is augmented in high-grade serous ovarian cancer

95010
Admin13.07.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

8010
Admin17.09.2021

Selective BCL-2 family inhibitors enable the functional

4407
Admin30.09.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

5907
Admin24.09.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

9701
Admin04.08.2021

Inhibition of Bcl-xL triggers apoptosis of BCR-ABL1 þ

5006
Admin04.08.2021

ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor

7503
Admin07.09.2021

(PDF) The Bcl-2/xL inhibitor ABT-263 increases the

5803
Admin14.07.2021

BCL-X L - selective inhibitor A-1331852 enhances the

1300
Admin20.09.2021

Bcl-2 Family - Apoptosis - Signaling Pathways

9302
Admin30.09.2021

(PDF) Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary

3402